Safety analysis of implanted peritoneal ports in gastric cancer with peritoneal metastasis
10.3969/j.issn.1000-8179.2019.01.122
- VernacularTitle:腹腔化疗港在胃癌腹膜转移中应用的安全性分析
- Author:
Kan XUE
1
;
Ziyu LI
;
Guojun YAN
;
Chao GAO
;
Shuangxi LI
;
Hui REN
;
Jiafu JI
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心一病区
- Keywords:
gastric cancer;
peritoneal metastasis;
implanted peritoneal ports;
complication;
safety
- From:
Chinese Journal of Clinical Oncology
2019;46(1):34-38
- CountryChina
- Language:Chinese
-
Abstract:
Objective: Intraperitoneal chemotherapy is increasingly being used in the treatment of gastric cancer with peritoneal me-tastasis, because the drug can directly act on the metastatic nodules. Repeated treatment can be administered through implanted ports, provided the ports are appropriately managed. Our study aimed to investigate the safety of peritoneal port implantation in pa-tients with gastric cancer with peritoneal metastasis. Methods: We retrospectively reviewed the records of patients undergoing intra-peritoneal port implantation for the administration of chemotherapy between June 2015 and June 2018 to investigate the causes of complications and to discuss their management and prevention. Results: Fifty-five ports were implanted in 54 patients with median us-age time of 8.4 (0.8-32.0) months. Complications occurred at 13 port sites (23.6%), including obstruction (7.3%), severe pain (5.5%), in-fection (3.6%), reflux (3.6%), access difficulty (1.8%), and subcutaneous mass formation (1.8%). The median interval from the time of port implantation to the development of complications was 2.1 months. No factor contributing to the complications was identified (P>0.05). Conclusions: Peritoneal port implantation to systematic chemotherapy in patients with gastric cancer with peritoneal metastasis is safe and feasible if the ports can be carefully managed.
